Dark

Check out our Level2View

ACST
Acasti Pharma, Inc. Common Stock
stock NASDAQ

Inactive

Oct 25, 2024

3.37USD-0.882%(-0.03)27,805

Pre-market

0.00USD-100.000%(-3.40)0

After-hours

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Jan 3, 2022

08:30AM EST Acasti Pharma Inc. (Acasti or the Company) (Nasdaq: ACST and TSX-V: ACST), today announced that Jan DAlvise, President and CEO of Acasti, will be presenting at the H.C. Wainwright BioConnect 2022 Conference being held virtually January 10-13, 2022. GlobeNewswire Inc

Dec 22, 2021

02:53PM EST Mid-Afternoon Market Update: CalAmp Drops After Q3 Results; Red Cat Holdings Shares Surge Benzinga

12:16PM EST Mid-Day Market Update: Nasdaq Rises Over 100 Points; Allakos Shares Plunge Benzinga

10:07AM EST Benzinga's Top Ratings Upgrades, Downgrades For December 22, 2021 Benzinga

05:06AM EST Oppenheimer Initiates Coverage On Acasti Pharma with Outperform Rating, Announces Price Target of $6 Benzinga

Dec 2, 2021

09:23AM EST Acasti Pharma's Hemorrhage Candidate Shows Encouraging PK Profile In Healthy Volunteers Benzinga

07:51AM EST The Daily Biotech Pulse: Moderna, Pfizer-BioNTech Ink New Vaccine Deals With UK, GSK-Vir Antibody Show Activity Against Omicron, Chemomab Gets Clearance Benzinga

07:22AM EST Acasti Pharma Announces Interim Data From Pivotal PK Study For GTX-104 Meets All Primary Endpoints RTTNews

07:02AM EST Acasti Pharma Announced Interim Data Met All Primary Endpoints for Pivotal PK Study for GTX-104 Benzinga

07:01AM EST Acasti Pharma Announces Interim Data Meets All Primary Endpoints GlobeNewswire Inc

Nov 24, 2021

08:30AM EST Acasti Pharma Inc. (Acasti or the Company) (Nasdaq: ACST and TSX-V: ACST), today announced that Jan DAlvise, President and CEO of Acasti Pharma, will be participating in the Benzinga All Access event taking place on December 2, 2021. GlobeNewswire Inc

Nov 12, 2021

05:35PM EST Acasti Pharma Inc. (Acasti or the Company) (Nasdaq: ACST and TSX-V: ACST), today announced the annual grant of stock options to its employees, executives and directors. GlobeNewswire Inc

Nov 10, 2021

07:54AM EST Acasti Pharma Q2 EPS $0.03 Up From $(0.01) YoY Benzinga

07:00AM EST Acasti Pharma Inc. (Acasti or the Company) (Nasdaq: ACST and TSX-V: ACST), today provided a business update and announced its operating and financial results for the second quarter of fiscal 2022 ended September 30, 2021. GlobeNewswire Inc

04:09AM EST Earnings Scheduled For November 10, 2021 Benzinga

Oct 6, 2021

08:36AM EDT Acasti Pharma Awarded Composition-Of-Matter Patents For GTX-101 In Europe, China And Mexico And For GTX-102 In Japan Benzinga

08:30AM EDT Acasti Pharma Awarded Composition-of-Matter Patents for GTX-101 in GlobeNewswire Inc

Sep 27, 2021

08:46AM EDT Acasti Pharma Announces Initiation Of Pharmacokinetic Bridging Study For GTX-104 RTTNews

08:30AM EDT Acasti Pharma Announces Initiation of Pharmacokinetic Bridging GlobeNewswire Inc

Sep 23, 2021

04:51PM EDT Acasti Pharma Shares Move Higher; Co Reports Form3 Filing Benzinga

Sep 22, 2021

08:33AM EDT Acasti Pharma Provides Update Following Acquisition Of Grace Therapeutics; Regains Compliance with Nasdaq Listing Standards Benzinga

08:30AM EDT Acasti Pharma Inc. (Acasti or the Company) (Nasdaq: ACST and TSX-V: ACST), today provided a business update and announced that the Nasdaq Stock Market (Nasdaq) has confirmed to Acasti that the Company has regained compliance with Nasdaqs minimum bid price requirement. GlobeNewswire Inc

Sep 14, 2021

08:30AM EDT Acasti Pharma Inc. (Acasti or the Company) (Nasdaq: ACST and TSX-V: ACST), today announced that it will be presenting at the Oppenheimer Fall Healthcare Summit being held virtually September 20-23, 2021. GlobeNewswire Inc

Sep 8, 2021

08:30AM EDT Acasti Pharma Inc. (Acasti or the Company) (Nasdaq: ACST and TSX-V: ACST) today announced that Jan DAlvise, President and Chief Executive Officer of Acasti Pharma, will be presenting at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually between September 13-15, 2021. GlobeNewswire Inc

Aug 27, 2021

08:43AM EDT Acasti Says 8-For-1 Reverse Stock Split Will Be implemented To Help Regain Nasdaq Compliance Benzinga

08:41AM EDT Acasti Pharma Announces Closing Of Merger With Grace Therapeutics Benzinga

08:41AM EDT Acasti Pharma Announces Successful Completion of its Merger with GlobeNewswire Inc

Aug 12, 2021

07:00AM EDT August 4th webcast replay discussing planned acquisition of Grace Therapeuticsavailable on the Companys website GlobeNewswire Inc

Jul 29, 2021

08:30AM EDT Reminder: Acasti Pharma to Host Conference Call on August 4th at GlobeNewswire Inc

Jul 23, 2021

08:30AM EDT Acasti Pharma Schedules Conference Call for August 4th at 1:00 PM GlobeNewswire Inc

Jun 22, 2021

07:18AM EDT Acasti Updates On Plans To Acquire Grace Therapeutics And Ongoing Strategic Process For CaPre RTTNews

07:05AM EDT Acasti Pharma FY21 EPS $(0.17), Up From $(0.30) YoY Benzinga

07:00AM EDT Acasti Pharma Inc. (Acasti or the Company) (Nasdaq: ACST and TSX-V: ACST) today announced its operating and financial results for the fiscal year ended March 31, 2021, and provided an update on its plans to acquire Grace Therapeutics and the ongoing strategic process for CaPre. GlobeNewswire Inc

May 17, 2021

07:00AM EDT Acasti Intends to Request Hearing Before Nasdaq Panel to Present GlobeNewswire Inc

May 12, 2021

05:31PM EDT ACASTI PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Acasti Pharma Inc. - ACST Business Wire

May 7, 2021

11:53AM EDT Acasti Pharma To Acquire Grace Therapeutics: Highlights Benzinga

07:02AM EDT Acasti Announces Definitive Agreement To Acquire Grace Therapeutics, Inc., Size Not Disclosed; Says Expects Cash At Closing Of ~$64M Will Be Principally Used To Pursue clinical Development Of First Two Assets Through Phase 3 Benzinga

07:00AM EDT Grace provides Acasti with a pipeline of rare and orphan disease programs, including 3 clinical stage assets that have received Orphan Drug Designation from the FDA GlobeNewswire Inc

Mar 8, 2021

05:31PM EST Acasti Pharma Says Recent 20.16M Common Stock Offering Priced For Gross Proceeds $21.7M Benzinga

05:30PM EST As required pursuant to the policies of the TSX Venture Exchange, Acasti Pharma Inc. (Acasti or the Company) (NASDAQ: ACST TSX-V: ACST) is providing an update on the use of its at-the market equity offering program. GlobeNewswire Inc

Feb 9, 2021

06:57AM EST Acasti Pharma Q3 EPS $(0.03) Up From $(0.14) YoY Benzinga

06:55AM EST Acasti Pharma Inc. (Acasti or the Company) (NASDAQ: ACST TSX-V: ACST) today announced its operating and financial results for the third quarter of fiscal 2021 ended December 31, 2020. GlobeNewswire Inc

Jan 27, 2021

06:55AM EST As required pursuant to the policies of the TSX Venture Exchange, Acasti Pharma Inc. (Acasti or the Company) (NASDAQ: ACST TSX-V: ACST) is providing an update on the use of its at-the market equity offering program. GlobeNewswire Inc

Jan 22, 2021

07:22AM EST The Daily Biotech Pulse: Fluidigm's Saliva-Based COVID Test Approved In Europe, China Backs Amarin's Vascepa Benzinga

Dec 23, 2020

03:28PM EST Acasti Pharma Confirms Mgmt., Board Unaware Of Any Material Change In Co.'s Operations To Account For Recent Increase In Market Activity Benzinga

03:24PM EST At the request of IIROC, Acasti Pharma Inc. (Acasti or the Company) (NASDAQ: ACST TSX-V: ACST) wishes to confirm that the Companys management and Board of Directors are unaware of any material change in the Companys operations that would account for the recent increase in market activity. GlobeNewswire Inc

Nov 16, 2020

06:56AM EST Acasti Pharma Q2 EPS $(0.06) Up From $(0.25) YoY Benzinga

06:55AM EST Acasti Pharma Inc. (Acasti or the Company) (NASDAQ: ACST TSX-V: ACST) today provided a business update and announced its operating and financial results for the second quarter of fiscal 2021 ended September 30, 2020. GlobeNewswire Inc

Oct 29, 2020

07:30AM EDT The Daily Biotech Pulse: Novartis Acquires Gene Therapy Company, Moderna's Japanese Vaccine Supply Deal Benzinga

Oct 1, 2020

04:30PM EDT Acasti Pharma Inc. (Acasti or the Corporation) (NASDAQ: ACST TSX-V: ACST), announces the voting results for the matters listed in its management information circular and proxy statement dated August 31, 2020 (the Circular) held at its Annual and Special Meeting of Shareholders on September 30, 2020 (the AGM). GlobeNewswire Inc

Sep 29, 2020

07:17AM EDT Acasti Pharma Begins Formal Process To Explore And Evaluate Strategic Alternatives RTTNews

07:03AM EDT Acasti Pharma Announces Review Process of Strategic Alternatives Benzinga

06:55AM EDT Acasti Announces Review Process of Strategic Alternatives GlobeNewswire Inc

Sep 16, 2020

06:55AM EDT Acasti Pharma Inc. (Acasti or the Company) (NASDAQ: ACST TSX-V: ACST) announced that it has appointed seasoned financial executive Brian D. Ford as its Chief Financial Officer, effective September 14, 2020. Mr. Ford assumes the responsibilities formerly held by Jean-Francois Boily, Vice-President, Finance, who recently resigned. GlobeNewswire Inc

Sep 11, 2020

07:00AM EDT Acasti Announces Filing and Mailing of Information Circular and GlobeNewswire Inc

Sep 2, 2020

01:24PM EDT Aegis Capital Downgrades Acasti Pharma to Hold, Lowers Price Target to $0.25 Benzinga

Sep 1, 2020

09:47AM EDT Benzinga's Top Upgrades, Downgrades For September 1, 2020 Benzinga

08:43AM EDT B. Riley FBR Downgrades Acasti Pharma to Neutral, Lowers Price Target to $0.5 Benzinga

06:16AM EDT Oppenheimer Downgrades Acasti Pharma to Perform Benzinga

Aug 31, 2020

02:30PM EDT Mid-Afternoon Market Update: Nasdaq Rises Over 100 Points; Regis Shares Drop After Q4 Results Benzinga

12:04PM EDT Mid-Day Market Update: Akcea Therapeutics Jumps Following Acquisition News; Acasti Pharma Shares Plummet Benzinga

07:50AM EDT Biopharmaceutical company Acasti Pharma Inc. (ACST) announced Monday top-line results for the Primary Endpoint (triglyceride reduction at 12 and 26 weeks) from its 278 patient Phase 3 TRILOGY 2 study evaluating the efficacy, safety and tolerability of CaPre in patients with severe hypertriglyceridemia. The study did not meet its primary endpoint. RTTNews

07:13AM EDT Acasti Pharma Reports Phase 3 TRILOGY 2 Study Of CaPre Did Not Achieve Statistical Significance For Primary Endpoint Benzinga

07:07AM EDT Acasti Pharma Says Phase 3 TRILOGY 2 Study Did Not Meet Its Primary Endpoint RTTNews

07:00AM EDT Acasti Pharma Reports Topline Triglyceride Results from Phase 3 GlobeNewswire Inc

Aug 13, 2020

08:38AM EDT Acasti Pharma Q1 EPS $(0.05) vs $(0.11) In Same Qtr. Last Year Benzinga

08:30AM EDT Acasti Pharma Provides Business Update for the First Quarter of GlobeNewswire Inc

Jul 31, 2020

08:28AM EDT Acasti Submits Statistical Analysis Plan To FDA; Remains On Track To Report TRILOGY 2 Topline Data On Or About Aug 31 RTTNews

07:55AM EDT Acasti Pharma Submits Statistical Analysis Plan To FDA And Remains On Track To Report TRILOGY 2 Topline Data On Or About August 31, 2020 Benzinga

07:55AM EDT Acasti Pharma Submits Statistical Analysis Plan to FDA and Remains GlobeNewswire Inc

Share